Taiho Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taiho Pharmaceutical Co., Ltd., explained in plain language.
Japanese pharmaceutical company focused on oncology and other therapeutic areas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Could a pill replace shots for MDS? early trial begins
Disease control Recruiting nowThis early-stage trial is testing an oral form of the cancer drug azacitidine (called ASTX030) for people with myelodysplastic syndrome (MDS). The goal is to see if the pill version reaches similar levels in the blood as the standard injection. About 40 adults with MDS will take …
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new immunotherapy combo shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
Disease control Recruiting nowThis phase 3 trial tests whether a combination of two experimental drugs (futibatinib and zimberelimab) plus standard chemotherapy can help people with advanced biliary tract cancer live longer compared to current standard immunotherapy combinations. The study enrolls about 784 a…
Phase: PHASE3 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill targets rare gene fault in advanced cancers
Disease control Recruiting nowThis study tests a new drug called TAS0953/HM06 in people with advanced solid tumors that have specific RET gene abnormalities. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well the drug shrinks tumors. About 244 adults with RET-altered non-small…
Phase: PHASE1, PHASE2 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC